Therapeutic disruption of RAD52–ssDNA complexation via novel drug-like inhibitors

RAD52 protein is a coveted target for anticancer drug discovery. Similar to poly-ADP-ribose polymerase (PARP) inhibitors, pharmacological inhibition of RAD52 is synthetically lethal with defects in genome caretakers BRCA1 and BRCA2 (∼25% of breast and ovarian cancers). Emerging structure activity re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhat, Divya S, Malacaria, Eva, Biagi, Ludovica Di, Razzaghi, Mortezaali, Honda, Masayoshi, Hobbs, Kathryn F, Hengel, Sarah R, Pichierri, Pietro, Spies, M Ashley, Spies, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
DNA Damage Sensing and Repair
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150327/
https://www.ncbi.nlm.nih.gov/pubmed/37139244
http://dx.doi.org/10.1093/narcan/zcad018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150327/
https://www.ncbi.nlm.nih.gov/pubmed/37139244
http://dx.doi.org/10.1093/narcan/zcad018

Ejemplares similares